WO2000074703A3 - Therapeutikum mit einem botulinum-neurotoxin - Google Patents

Therapeutikum mit einem botulinum-neurotoxin Download PDF

Info

Publication number
WO2000074703A3
WO2000074703A3 PCT/DE2000/001777 DE0001777W WO0074703A3 WO 2000074703 A3 WO2000074703 A3 WO 2000074703A3 DE 0001777 W DE0001777 W DE 0001777W WO 0074703 A3 WO0074703 A3 WO 0074703A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotoxins
therapeutic agent
botulinum neurotoxin
botulinum
neurotoxin
Prior art date
Application number
PCT/DE2000/001777
Other languages
English (en)
French (fr)
Other versions
WO2000074703A2 (de
WO2000074703B1 (de
Inventor
Hans Bigalke
Juergen Frevert
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Hans Bigalke
Juergen Frevert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000074703(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL352468A priority Critical patent/PL198958B1/pl
Priority to UA2002010181A priority patent/UA72253C2/uk
Priority to AT00943666T priority patent/ATE258803T1/de
Priority to EP00943666A priority patent/EP1185291B2/de
Priority to JP2001501237A priority patent/JP2003505343A/ja
Priority to IL14697400A priority patent/IL146974A0/xx
Priority to DK00943666T priority patent/DK1185291T3/da
Priority to AU58047/00A priority patent/AU774590B2/en
Priority to DE10081516T priority patent/DE10081516D2/de
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh, Hans Bigalke, Juergen Frevert filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority to EA200200017A priority patent/EA004202B1/ru
Priority to MXPA01012540A priority patent/MXPA01012540A/es
Priority to US10/018,373 priority patent/US7964199B1/en
Priority to SI200030341T priority patent/SI1185291T1/xx
Priority to DE50005208T priority patent/DE50005208D1/de
Priority to CA002376193A priority patent/CA2376193C/en
Publication of WO2000074703A2 publication Critical patent/WO2000074703A2/de
Publication of WO2000074703A3 publication Critical patent/WO2000074703A3/de
Publication of WO2000074703B1 publication Critical patent/WO2000074703B1/de
Priority to IL146974A priority patent/IL146974A/en
Priority to NO20015964A priority patent/NO20015964L/no
Priority to HK02108892.0A priority patent/HK1047403A1/xx
Priority to US13/068,439 priority patent/US20110217287A1/en
Priority to US13/303,973 priority patent/US8398998B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Pharmazeutische Zubereitung, enthaltend eines der Botulinum-Neurotoxine von Clostridium botulinum der Typen A, B, C, D, E, F oder G oder ein Gemisch von zwei oder mehr dieser Neurotoxine, dadurch gekennzeichnet, dass das Neurotoxin bzw. das Gemisch der Neurotoxine frei ist von den komplexierenden Proteinen, die natürlicherweise zusammen mit den Neurotoxinen die Botulinum-Neurotoxin-Komplexe bilden.
PCT/DE2000/001777 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin WO2000074703A2 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EA200200017A EA004202B1 (ru) 1999-06-07 2000-05-26 Терапевтическое средство с ботулиническим нейротоксином
MXPA01012540A MXPA01012540A (es) 1999-06-07 2000-05-26 Agente terapeutico que contiene una neurotoxina de botulismo.
AT00943666T ATE258803T1 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
EP00943666A EP1185291B2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
JP2001501237A JP2003505343A (ja) 1999-06-07 2000-05-26 ボツリヌス神経毒を含む治療薬
IL14697400A IL146974A0 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
DK00943666T DK1185291T3 (da) 1999-06-07 2000-05-26 Terapeutisk middel til et botulinum-neurotoksin
AU58047/00A AU774590B2 (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
DE10081516T DE10081516D2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem Botulinum-Neurotoxin
UA2002010181A UA72253C2 (uk) 1999-06-07 2000-05-26 Застосування ботулінічного нейротоксину, вільного від комплексоутворюючих білків, для одержання фармацевтичного засобу
CA002376193A CA2376193C (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
PL352468A PL198958B1 (pl) 1999-06-07 2000-05-26 Zastosowanie neurotoksyny botulinowej z Clostridium botulinum
DE50005208T DE50005208D1 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
SI200030341T SI1185291T1 (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
US10/018,373 US7964199B1 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
NO20015964A NO20015964L (no) 1999-06-07 2001-12-06 Terapeutisk middel omfattende et botulinum-neurotoksin
IL146974A IL146974A (en) 1999-06-07 2001-12-06 The use of botulinum neurotoxin for drug preparation
HK02108892.0A HK1047403A1 (en) 1999-06-07 2002-12-06 Therapeutic agent comprising a botulinum neurotoxin
US13/068,439 US20110217287A1 (en) 1999-06-07 2011-05-11 Therapeutic composition comprising a botulinum neurotoxin
US13/303,973 US8398998B2 (en) 1999-06-07 2011-11-23 Therapeutic composition comprising a botulinum neurotoxin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19925739.6 1999-06-07
DE19925739A DE19925739A1 (de) 1999-06-07 1999-06-07 Therapeutikum mit einem Botulinum-Neurotoxin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/018,373 A-371-Of-International US7964199B1 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
US13/068,439 Continuation US20110217287A1 (en) 1999-06-07 2011-05-11 Therapeutic composition comprising a botulinum neurotoxin

Publications (3)

Publication Number Publication Date
WO2000074703A2 WO2000074703A2 (de) 2000-12-14
WO2000074703A3 true WO2000074703A3 (de) 2001-04-26
WO2000074703B1 WO2000074703B1 (de) 2001-06-07

Family

ID=7910318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/001777 WO2000074703A2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin

Country Status (27)

Country Link
US (3) US7964199B1 (de)
EP (1) EP1185291B2 (de)
JP (2) JP2003505343A (de)
KR (1) KR100466407B1 (de)
CN (2) CN101062009A (de)
AR (1) AR024306A1 (de)
AT (1) ATE258803T1 (de)
AU (1) AU774590B2 (de)
CA (1) CA2376193C (de)
CO (1) CO5170431A1 (de)
CZ (1) CZ20014351A3 (de)
DE (3) DE19925739A1 (de)
DK (1) DK1185291T3 (de)
EA (1) EA004202B1 (de)
ES (1) ES2215056T5 (de)
GE (1) GEP20043200B (de)
HK (1) HK1047403A1 (de)
HU (1) HUP0201530A3 (de)
IL (2) IL146974A0 (de)
MX (1) MXPA01012540A (de)
NO (1) NO20015964L (de)
PL (1) PL198958B1 (de)
PT (1) PT1185291E (de)
TW (1) TWI251492B (de)
UA (1) UA72253C2 (de)
WO (1) WO2000074703A2 (de)
ZA (1) ZA200110074B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
CA2496005C (en) * 2002-08-19 2013-07-23 Ira Sanders Use of botulinum toxin for the treatment of fine wrinkles and pore size
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20060153877A1 (en) * 2003-06-20 2006-07-13 Shunji Kozaki Remedies for dissease with hypermyotonia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
PT1729821E (pt) 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EA011652B1 (ru) * 2004-07-26 2009-04-28 Мерц Фарма Гмбх Унд Ко. Кгаа Терапевтические композиции с нейротоксином ботулина
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
EP1799254A1 (de) * 2004-09-27 2007-06-27 Merz Pharma GmbH & Co.KGaA Clostridium-neurotoxine zur verwendung bei der gewebeheilung
EP1861112A4 (de) 2005-03-03 2009-07-22 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen
JP5006803B2 (ja) * 2005-03-03 2012-08-22 アラーガン、インコーポレイテッド クロストリジウム・バクテリアの培地およびクロストリジウム毒素を得るための方法
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
CN101194010B (zh) 2005-06-17 2013-04-03 莫茨药物股份两合公司 用于发酵制备生物活性化合物的设施和方法
KR101423272B1 (ko) 2005-11-17 2014-07-30 레반스 테라퓨틱스, 아이엔씨. 감소된 비-독소 단백질을 갖는 보툴리눔 독소의 국소 적용및 경피 전달을 위한 조성물 및 방법
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP2048156A1 (de) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Prozess zur Bereitstellung eines temperaturstabilen Muskelrelaxans auf der Basis der neurotoxischen Komponente von Botulintoxin
CA2686637A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2072039A1 (de) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
EP2072057A1 (de) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Frühe Verabreichung von Botulinumtoxin bei der Behandlung von zerebrovaskulären Ereignissen und Rückenmarksverletzungen
US8540987B2 (en) * 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
SI3031825T1 (sl) * 2008-03-14 2019-12-31 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
ES2571792T3 (es) * 2008-03-31 2016-05-26 The Chemo-Sero-Therapeutic Res Inst Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1
US8748151B2 (en) 2008-08-29 2014-06-10 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
DK2161033T3 (da) * 2008-09-09 2013-08-05 Susanne Dr Grafe Botulinustoxin til at indføre midlertidig infertilitet i et hvirveldyr (f.eks. et menneske)
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2248518B1 (de) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen.
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
PT2490986T (pt) * 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
CN103501802B (zh) * 2011-06-27 2016-03-16 金相德 皮肤疤痕治疗用药物组合物及利用其的皮肤疤痕治疗方法
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
BR112016001730B1 (pt) * 2013-07-30 2023-04-11 Merz Pharma Gmbh & Co. Kgaa Processo para a preparação de um componente neurotóxico altamente puro de uma toxina clostridium botulinum, composição farmacêutica e uso de um componente neurotóxico altamente puro de uma toxina clostridium botulinum
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
ES2762951T3 (es) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche Nuevo uso terapéutico de la neurotoxina botulínica serotipo A
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
CN110691579A (zh) 2017-03-22 2020-01-14 邦蒂公司 用于治疗的肉毒杆菌神经毒素
EP3600384A1 (de) 2017-03-24 2020-02-05 Merz Pharma GmbH & Co. KGaA Verbesserte verwendung von botulinneurotoxin in der behandlung von sialorrhoe
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
EP3860640A1 (de) 2018-10-02 2021-08-11 Merz Pharma GmbH & Co. KGaA Neuartige verwendungen von botulinumneurotoxin zur behandlung von lipoödem
JP2022521237A (ja) 2019-02-21 2022-04-06 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン 振戦治療のためのボツリヌス神経毒素の新規用途
CA3177835A1 (en) 2020-06-05 2021-12-09 Susanna ROLL High dose and low volume botulinum toxin treatment of facial wrinkles
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1996039167A1 (en) * 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699078B1 (de) 1993-05-14 2005-01-05 Stephen S. Arnon Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
EP0770395B1 (de) 1993-12-28 2001-10-24 Allergan Sales, Inc. Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
CA2505930C (en) * 1997-07-15 2008-01-29 Richard A. Schmidt Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
IN2012DN00733A (de) * 2009-07-02 2015-06-19 Merz Pharma Gmbh & Co Kgaa

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1996039167A1 (en) * 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EDITORIAL: "botulinum toxin", THE LANCET, vol. 340, no. 19/26, December 1992 (1992-12-01), pages 1508 - 1509, XP002158435 *
GOESCHEL HILKE ET AL: "Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequences.", EXPERIMENTAL NEUROLOGY, vol. 147, no. 1, 1997, pages 96 - 102, XP002158434, ISSN: 0014-4886 *
KEEN M ET AL: "Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 94, no. 1, July 1994 (1994-07-01), pages 94 - 99, XP000982177 *
NAUMANN M ET AL: "Depletion of neutralising antibodies resensitizes a secondary non-responder to botulinum A neurotoxin.", JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol. 65, no. 6, December 1998 (1998-12-01), pages 924 - 927, XP000979025, ISSN: 0022-3050 *

Also Published As

Publication number Publication date
AU774590B2 (en) 2004-07-01
EP1185291B2 (de) 2010-10-27
HK1047403A1 (en) 2003-02-21
NO20015964L (no) 2002-01-30
EP1185291A2 (de) 2002-03-13
ZA200110074B (en) 2003-03-06
JP2007238627A (ja) 2007-09-20
US7964199B1 (en) 2011-06-21
MXPA01012540A (es) 2004-09-27
NO20015964D0 (no) 2001-12-06
EP1185291B1 (de) 2004-02-04
HUP0201530A3 (en) 2002-10-28
CA2376193A1 (en) 2000-12-14
IL146974A (en) 2007-05-15
CN101062009A (zh) 2007-10-31
IL146974A0 (en) 2002-08-14
DE19925739A1 (de) 2000-12-21
PT1185291E (pt) 2004-06-30
HUP0201530A2 (en) 2002-09-28
ATE258803T1 (de) 2004-02-15
AR024306A1 (es) 2002-09-25
CN1354670A (zh) 2002-06-19
US20120088732A1 (en) 2012-04-12
KR100466407B1 (ko) 2005-01-27
JP2003505343A (ja) 2003-02-12
TWI251492B (en) 2006-03-21
EA004202B1 (ru) 2004-02-26
WO2000074703A2 (de) 2000-12-14
CN100389820C (zh) 2008-05-28
US8398998B2 (en) 2013-03-19
US20110217287A1 (en) 2011-09-08
AU5804700A (en) 2000-12-28
DE50005208D1 (de) 2004-03-11
EA200200017A1 (ru) 2002-06-27
ES2215056T3 (es) 2004-10-01
DK1185291T3 (da) 2004-04-05
CZ20014351A3 (cs) 2002-06-12
ES2215056T5 (es) 2011-03-15
KR20020008214A (ko) 2002-01-29
UA72253C2 (uk) 2005-02-15
CA2376193C (en) 2008-09-16
DE10081516D2 (de) 2001-09-13
PL198958B1 (pl) 2008-08-29
GEP20043200B (en) 2004-03-25
PL352468A1 (en) 2003-08-25
CO5170431A1 (es) 2002-06-27
WO2000074703B1 (de) 2001-06-07

Similar Documents

Publication Publication Date Title
WO2000074703A3 (de) Therapeutikum mit einem botulinum-neurotoxin
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
WO2007044809A3 (en) Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
EP2266600A3 (de) Therapeutische Zusammensetzung mit Botulinum-Neurotoxin
AU1482102A (en) Complexes of phosphate derivatives
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
ATE252601T1 (de) Lang wirkende insulinotrope peptide
IL130190A0 (en) Methods and compositions for polypeptide engineering
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
ATE221386T1 (de) Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin
WO2002008268A3 (en) Leucine-based motif and clostridial neurotoxins
IL160641A0 (en) Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
EP1295609A4 (de) Medikamente mit gemischten aktiven stoffen
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
AU1378395A (en) Metal chelators
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
YU23302A (sh) Farmaceutski preparati fibrinolitičkog agensa
WO1998008505A8 (en) Pharmaceutical compounds
WO2001072264A3 (de) Pro-liposomal verkapselte zubereitungen (iv)
WO1999064587A8 (fr) Polypeptides possedant une activite de type beta-secretase
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808641.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
REF Corresponds to

Ref document number: 10081516

Country of ref document: DE

Date of ref document: 20010913

WWE Wipo information: entry into national phase

Ref document number: 10081516

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: PV2001-4351

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020017015668

Country of ref document: KR

Ref document number: PA/a/2001/012540

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2376193

Country of ref document: CA

Ref document number: 2376193

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2001 501237

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/10074

Country of ref document: ZA

Ref document number: 10018373

Country of ref document: US

Ref document number: 200110074

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 58047/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000943666

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200200017

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020017015668

Country of ref document: KR

WD Withdrawal of designations after international publication

Free format text: DE

WWP Wipo information: published in national office

Ref document number: 2000943666

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-4351

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000943666

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017015668

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 58047/00

Country of ref document: AU